miércoles, 7 de octubre de 2026
BuscarExplore
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
Source document· February 12, 2026

Aduro Clean Technologies franchit une étape clé avec l’entrée en phase d’exploitation de son usine pilote NGP

View original at globenewswire.com
Aduro Clean Technologies franchit une étape clé avec l’entrée en phase d’exploitation de son usine pilote NGP LONDON, Ontario, 12 févr. 2026 (GLOBE NEWSWIRE) -- Aduro Clean Technologies Inc…
Opening lines of the source · short snapshot — read the full document at the original

Lo que extrajimos de esta fuente

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • The FOAK installation site is selected, and the work performed in London will directly guide design and integration while strengthening the Company's readiness for the next phase of scale-up.

    80% confidence
  • After commissioning, our priority shifted to operating the integrated system and operational learning. The NGP pilot plant extends the work done with the R2 continuous flow reactor, allowing us to evaluate mixed plastic samples from customer programs and real-world sources under extended, integrated conditions.

    80% confidence
  • The NGP pilot plant is operating according to expectations, and initial campaigns correspond to planned tests.

    80% confidence
  • This milestone reflects rigorous execution by our engineering, operations, and project management teams. With the launch of structured testing operations, the NGP pilot plant becomes a major asset for our commercialization trajectory and stakeholder engagement strengthening.

    80% confidence
  • These campaigns aim to optimize operating parameters to maximize yields and ensure consistent performance despite feedstock variability, while validating design assumptions for the FOAK industrial facility.

    80% confidence
  • Aduro is well-positioned to generate operational and environmental data supporting advancement of its commercialization program.

    80% confidence
Lo que sabemos · la inteligencia detrás de esta página
En vivo desde el sustrato
Lo que estamos viendo
Obesity and Immunology Readouts, Big Pharma M&A and AI-Designed Drugs Converge Into a Q4 2026 Catalyst Wave
Late-stage data and deal activity are clustering ahead of Q4 2026. Novo Nordisk's CagriSema won Best Abstract at EASD 2026 for its brain and body (fMRI/MRI) data, Lilly showed ADtouch results for EBGLYSS and agreed to buy Merida Biosciences for $2.9B, and Merck's tulisokibart hit its Phase 2b endpoints. A key regulatory catalyst follows: the FDA PDUFA date for the ivonescimab BLA on 2026-11-14. AI-designed rentosertib showing anti-aging effects adds a speculative AI-drug-discovery thread, while QAIAx's microcities trial and QIII pilot (planned 2027-01-01) are peripheral, forecast-only items.
Nuestra lectura de los datos ›
Señales que seguimos
Satellite-Terrestrial Network Integration Acceleration
Increased investment and launches in hybrid satellite-cellular networks across telecom industry; competitive responses from other carriers; regulatory activity around satellite spectrum; expansion of emergency/rural connectivity use cases
Patrones que observamos ›
Donde las fuentes discrepan
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
Señalamos los conflictos abiertamente ›
Verificado recientemente
✓ Verificado con la fuente original
4,985
hechos rastreados a su fuente — y señalamos los que no se sostienen.
101 entidades seguidas4,985 hechos verificados con la fuente5,351 documentos fuente archivados
Consulta estos datos → isubstrate.com